RecruitingPhase 1NCT07346846
A Study of BGM-2121 in Patients With Advanced Solid Tumors
A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors
Sponsor
BioGate Precision Medicine Corp.
Enrollment
35 participants
Start Date
Mar 10, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- With either gender aged ≥ 18 years,
- Has a confirmed diagnosis of advanced solid tumor(s),
- The subject has received and failed standard-of-care anti-cancer therapy
- Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
- ...
Exclusion Criteria4
- Has any ongoing toxicity from previous anti-cancer treatments
- Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
- History of another primary malignancy within the last three years
- ...
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBGM-2121
BGM-2121 treatment
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07346846
Related Trials
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT075614371 location
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT0641368011 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
NCT074390941 location
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT067232367 locations